<?xml version="1.0" encoding="UTF-8"?>
<p id="p0095">To facilitate interpretation of anti-HDV prevalence estimates among patients diagnosed with cirrhosis or HCC, we calculated the PAF of HDV for cirrhosis and HCC among HBsAg-positive people. We used methodology recommended by the WHO, where PAF = prevalence among cases × [(odds ratio − 1)/odds ratio].
 <xref rid="bib18" ref-type="bibr">
  <sup>18</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib19" ref-type="bibr">
  <sup>19</sup>
 </xref> where OR is used as an approximation for the disease risk ratio of exposed (anti-HDV positive) 
 <italic>vs.</italic> non-exposed (anti-HDV negative) participants. The OR calculation included HBsAg-positive general populations or asymptomatic HBsAg-positive people (as defined above), using empirical data from the highest quality and largest sample available from the same geographic region as the control population.
 <xref rid="bib3" ref-type="bibr">
  <sup>3</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib20" ref-type="bibr">
  <sup>20</sup>
 </xref>
</p>
